Joan Calvet
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Background The relationship between hidradenitis suppurativa ( HS) and arthritis is well‐established; however, the impact of their combined disease burden and the associated treatment pattern has not been determined yet. This study aimed to assess disease burden and therapeutic approaches in HS patients with and without arthritis and estimate arthritis prevalence and subtypes. Methods A multicenter, retrospective, case–control study of 272 adults (69 with HS and arthritis; 203 with HS only), drawn from a hospital‐based cohort of 3644 HS patients across 10 Spanish centers. Controls were matched 1:3 by sex, age, and HS duration. Statistical analysis included non‐parametric tests, logistic regression, and linear mixed‐effects models adjusted for confounders. Results HS patients with arthritis had higher rates of immune‐mediated diseases, including inflammatory bowel disease (odds ratio [ OR] 9.44, p < 0.0001) and psoriasis ( OR 2.99, p = 0.0038), higher Dermatology Life Quality Index ( DLQI) scores (6.30 vs. 4.03, p = 0.031), more dermatology visits (7.00 vs. 5.00, p = 0.0077), and greater biologic therapy use (72.07% vs. 39.90%, p < 0.0001). The prevalence of arthritis among HS patients was 1.70% (95% confidence interval [ CI] : 1.00%–2.70%), with spondyloarthritis being the most common subtype (66.6%). Conclusions HS patients with arthritis have a greater disease burden and higher biologic therapy utilization, emphasizing the need for interdisciplinary care and optimizing resources.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Objectives The aim of the present study was to describe demographic, clinical, and immunological characteristics of SLE patients with anti-La/SSB antibodies positive versus anti-La/SSB negative patients. Methods Retrospective cross-sectional study, including all patients with SLE (≥4 ACR-1997 criteria) recruited in RELESSER registry. Sociodemographic, clinical, serological and comorbidities variables were collected. Anti-Ro-/La + patients were compared with the rest of the patients. Results In a study involving 4219 systemic lupus erythematosus (SLE) patients, 44/3893 (1.1%) were found to be positive for isolated anti-La/SSB antibodies. The mean age was 33.77 years, with a majority being female (88.6%) and Caucasian (90.5%). The most frequent comorbidities were smoking (48.8%), dyslipidemia (47.7%), and arterial hypertension (31.8%). Photosensitivity and mucosal ulcers were more common in anti-Ro+/La + patients compared to anti-Ro+/La- and anti-Ro-/La- patients. Anti-Ro+/La + patients had a lower frequency of lupus nephritis compared to anti-Ro+/La- patients. A multivariable regression model, considering various confounding factors, was applied to compare anti-La/SSB positive patients with negative ones. Isolated anti-La/SSB positive patients showed a lower occurrence of lupus nephritis and a higher frequency of cardiac manifestations. Conclusions The study suggests that patients with isolated anti-La/SSB antibodies may have a unique clinical profile, with a potential protective effect against lupus nephritis but an increased likelihood of cardiac manifestations.
Year:
2025
Introduction Considering the growing recognition of the association between hidradenitis suppurativa (HS) and spondyloarthritis (SpA), this study addresses a gap in clinical practice in HS consultation: the absence of a validated arthritis screening tool. Methods Drawing on interdisciplinary collaboration between dermatology and rheumatology, we assayed a modified version of the PURE-4 tool: patient and dermatologist PURE-5 (p- and d- PURE-5), adapted to reflect clinical features relevant to this population. Results Of 214 HS patients, 125 (58.4%) were male, with a median age of 42 years (IQR 30–49). Buttock involvement was observed in 64 patients (29.9%) and was more common in males (35.7%) than in females (21.6%) (p = 0.26). Of the 214 patients, 82 (38.3%) answered negatively to all questions, while 118 (55.6%) answered positively to at least one question in the pPURE-5 but were later dismissed by the trained dermatologist after a more detailed interview. Finally, fourteen patients (6.5%) were referred to Rheumatology due to a positive dPURE-5. Of these, 2 (14.3%) were diagnosed with inflammatory chronic arthritis, yielding a PPV of 14.3%. Conclusion To conclude, the PURE-5 questionnaire appeared valuable for guiding anamnesis and facilitating rheumatology referrals. Even so, there is still a need for new and validated screening tools for detecting arthritis in HS population.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (15)
Juan Francisco Delgado
Researcher
Institute of Research and Innovation Parc Tauli
Antonio Fernandez-Nebro
Profesor titular acreditado como catedrático (Reader)
University of Malaga
Patricia Garbayo-Salmons
Institute of Research and Innovation Parc Tauli
Emili Masferrer i Niubò
Professor associat
Universitat de Vic - Universitat Central de Catalunya
Hèctor Corominas
Professor titular / Professor Tenure track position
Universitat Autònoma de Barcelona (UAB)
Júlia Verdaguer-Faja
Universitat Autònoma de Barcelona
Maria Llop Vilaltella
Institute of Research and Innovation Parc Tauli
Mireia Moreno Martínez-Losa
Institute of Research and Innovation Parc Tauli
Paloma Vela Casasempere
Instituto de Investigación Sanitaria y Biomédica de Alicante
Cristina Campos Fernández
Head of the Rheumatology Department.
Generalitat Valenciana
José Luis Andreu
Head
Hospital Universitario Puerta del Hierro Majadahonda
Eugenio De Miguel
MD, PhD, Prof
La Paz University Hospital
Alejandro Molina-Leyva
Head of Section
Hospital Universitario Virgen del Rocío
Cristina Macía-Villa
HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL
VICENTE EXPÓSITO GIL
AYUNTAMIENTO DE CHIVA
Make your next move.
Prepare your application
Review drafts before you send them.